Revance Therapeutics, Inc. (RVNC) Reports Q3 Loss, Lags Revenue Estimates
Portfolio Pulse from
Revance Therapeutics, Inc. (RVNC) reported a Q3 loss of $0.37 per share, missing the Zacks Consensus Estimate of a $0.35 loss. This is an improvement from the $0.74 loss per share a year ago.
November 08, 2024 | 12:30 am
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Revance Therapeutics reported a Q3 loss of $0.37 per share, which was worse than the expected $0.35 loss. Despite missing estimates, the loss is an improvement from the previous year's $0.74 per share.
The reported loss per share was worse than expected, which is typically negative for stock prices. However, the improvement from the previous year's loss may mitigate some negative impact.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100